The estimated Net Worth of Timothy M Mayleben is at least $2.1 Milhão dollars as of 30 December 2020. Mr. Mayleben owns over 10,700 units of Esperion Therapeutics stock worth over $213,495 and over the last 11 years he sold ESPR stock worth over $804,900. In addition, he makes $1,080,850 as President, Chief Executive Officer, e Director at Esperion Therapeutics.
Timothy has made over 20 trades of the Esperion Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 10,700 units of ESPR stock worth $22,470 on 30 December 2020.
The largest trade he's ever made was exercising 42,550 units of Esperion Therapeutics stock on 16 July 2015 worth over $44,252. On average, Timothy trades about 3,982 units every 57 days since 2013. As of 30 December 2020 he still owns at least 122,698 units of Esperion Therapeutics stock.
You can see the complete history of Mr. Mayleben stock trades at the bottom of the page.
Timothy M. Mayleben serves as President, Chief Executive Officer, Director of the Company. He has served as our President and Chief Executive Officer since December 2012 and as a member of our Board since February 2010. Prior to joining Esperion, Mr. Mayleben was President, CEO and a director of Vericel Corporation (NASDAQ: VCEL) (formerly Aastrom Biosciences). Previously, Mr. Mayleben was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, he was the COO of the original Esperion, until its acquisition by Pfizer in 2004. Mr. Mayleben is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaléo Pharma and Marinus Pharmaceuticals (NASDAQ: MRNS) as well as the Wolverine Venture Fund. Mr. Mayleben previously served as a director of Loxo Oncology, Inc. (NASDAQ: LOXO) prior to its acquisition by Eli Lilly. Mr. Mayleben earned an M.B.A., with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from the University of Michigan, Ross School of Business.
As the President, Chief Executive Officer, e Director of Esperion Therapeutics, the total compensation of Timothy Mayleben at Esperion Therapeutics is $1,080,850. There are no executives at Esperion Therapeutics getting paid more.
Timothy Mayleben is 59, he's been the President, Chief Executive Officer, e Director of Esperion Therapeutics since 2012. There are 4 older and 11 younger executives at Esperion Therapeutics. The oldest executive at Esperion Therapeutics Inc. is Antonio Gotto, 84, who is the Independent Director.
Timothy's mailing address filed with the SEC is 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD RD, RADNOR, PA, 19087.
Over the last 11 years, insiders at Esperion Therapeutics have traded over $197,978,412 worth of Esperion Therapeutics stock and bought 6,755,593 units worth $134,445,709 . The most active insiders traders include Patrick G Enright, Target N Vbb Biotech Ag Bio..., eNicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of $145,621. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth $411.
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Esperion Therapeutics executives and other stock owners filed with the SEC include: